Friday, May 3 - Saturday, May 4, 2024
Hyatt Regency Lake Tahoe Resort, Incline Village, Nevada
Please contact Karen Sultana for questions at sultanak@med.unr.edu.
Sponsored by: William N. Pennington Cancer Institute
2nd Annual Pennington Cancer Institute Cancer Conference
Overview
Cancer screening, early detection, and treatment are rapidly changing, with new technologies and therapies being introduced. This year almost 2 million Americans will be diagnosed with cancer. Therefore, it is critical for primary care providers to remain current with guidelines. Understanding the initial cancer therapy is also essential for optimal patient care, as patients often seek information from multiple sources, including their primary providers. This conference will address numerous topics related to common forms of cancer commonly seen and often diagnosed by PCPs.
Who Should Attend
Physicians, Advanced Practice Nurses, Nurses, Physician Assistants, Medical Researchers, and Pharmacists
Registration
This is an in-person CME event
Includes welcome reception, Saturday continental breakfast and lunch, and CME/CE credit. The early registration deadline is April 10, 2024. After April 10, 2024, registration increases.
Early registration (on or before April 10, 2024)
Friday only: $50
Saturday: $100
Both days: $125
Late registration (April 11 - 29, 2024)
Friday only: $70
Saturday: $125
Both days: $150
Registration for this conference has closed, please contact sultanak@med.unr.edu for questions.
Discounted registration is available for UNR Med Faculty, Medical Students and Residents. For additional information, please call (775) 784-8078 or sultanak@med.unr.edu.
Cancellation Policy
Cancellations received by April 12, 2024 will receive a full refund less a $25 cancellation fee. Cancellations after April 12, 2024 are non-refundable.
Program Support
This program is supported by William N. Pennington Cancer Institute.
The contents are those of the author(s) and do not necessarily represent the official views of Renown Health.
| Time | Event |
|---|---|
| 1:00 - 1:10 p.m. | Welcome and Introduction Lee Schwartzberg, M.D., FACP |
| What’s New, What’s Around the Corner Sessions | |
| 1:10 - 1:55 p.m. | Opening Keynote Managing the Tsunami of Medical Information: AI and Beyond David R. Penberthy, MD |
| 1:55 - 2:40 p.m. | Breast Cancer Joyce O’Shaughnessy, M.D. |
| 2:40 - 3:35 p.m. | Lung Cancer Edward S. Kim, MD, MBA, Vice Physician-in-Chief and Professor, City of Hope National Medical Center |
| 3:35 - 4:00 p.m. | Break and Exhibits |
| 4:00 - 4:45 p.m. | Colorectal Cancer Tanios Bekaii-Saab, M.D. |
| 4:45 - 5:15 p.m. | Precision Medicine in Advanced Prostate Cancer: Is it a Reality? Christopher P. Evans, M.D. |
| 5:15 - 5:45 p.m. | Orthopedic Oncology Babe Westlake, D.O. |
| 5:45 - 6:30 p.m. | Welcome Reception in Exhibit Space |
| Time | Event |
|---|---|
| 8:00 - 9:00 a.m. | Breakfast and Product Theater by Natera in Exhibit Space (non-CME) |
| 9:00 - 9:30 a.m. | Opening Remarks: Trends in Cancer 2024 Lee Schwartzberg, M.D., FACP |
| 9:30 - 10:00 a.m. | Pennington Cancer Institute Update Max Coppes, M.D., Ph.D., MBA |
| 10:00 - 10:30 a.m. | Targeted Bronchoscopy on Lung Cancer Screened Lesions Farah Madhani-Lovel, M.D. |
| 10:30 - 10:50 a.m. | Break and Exhibits |
| 10:50 - 11:20 a.m. | High and Low-Risk Breast Cancer Screening by Genetics Joseph Grzymski, Ph.D. |
| 11:20 - 11:50 p.m. | Prostate Cancer Screening and Early Detection Christopher P. Evans, M.D. |
| 11:50 - 12:20 p.m. | Lung Tumor Board Joel France, D.O. Kathleen Graham, D.O. Jocelyn Mata, OSW-C, MSW Suchit Patel, M.D., Ph.D. Katharine Thomas, M.D. |
| 12:20 - 1:30 p.m. | Lunch and Product Theater by Daiichi Sankyo (Non-CME) |
| 1:30 - 2:00 p.m. | CNS Tumors Rima Sestokas Rindler, MD Jocelyn Mata, OSW-C, MSW |
| 2:00 - 2:45 p.m. | GI Tumor Board Dzmitry Fursevich, M.D. Christos Galanopoulos, M.D. Garrett Green, M.D. Jennifer Jeung, M.D. Nicholas Manguso, M.D. Jocelyn Mata, OSW-C, MSW Harry Menon, D.O. Michael Thomas, M.D., Ph.D. |
| 2:45 - 3:00 p.m. | Break and Exhibits |
| 3:00 - 3:30 p.m. | Palliative Care is for Any Cancer Aaron Dieringer, M.D., Ph.D. |
| 3:30 - 4:00 p.m. | Breast Cancer Tumor Board Michelle Chu, M.D. Christie Elliot, M.D. Michael Hardacre, M.D. George Krakora, M.D. Jocelyn Mata, OSW-C, MSW Colleen O’Kelly Priddy, M.D. Lee Schwartzberg, M.D., FACP |
| 4:00 - 4:10 p.m. | Closing Remarks Lee Schwartzberg, M.D., FACP |
Hyatt Regency Lake Tahoe Resort
111 County Club Drive
Incline Village, Nevada 89451
Directions
Discounted room guest room rates are available for conference attendees on Friday, May 3rd, and Saturday, May 4. Room rates do not include local and state taxes. All rooms are subject to a resort fee of $40 per room, per night.
Single or Double Occupancy: $219 (plus applicable taxes and resort fee)
Triple Occupancy: $244 (plus applicable taxes and resort fee)
Quadruple Occupancy: $269 (plus applicable taxes and resort fee)
Rooms are subject to availability, and the reservation deadline is April 10, 2024 to receive the discounted rates.
Guests may make reservations online or by calling (775) 832-1234. Mention the Renown Cancer Institute Conference to receive the discounted group rate.
Renown Cancer Center Institute Conference Online Hotel Reservation Booking
Hotel Parking
On-site self-parking is $20 per car, per night for conference attendees for May 3-4, 2024.
Exhibit opportunities are available. Please see the exhibit prospectus for additional information.
Presenting Sponsor: $15,000 (one available)
- Three 6’ draped display tables
- Complimentary registration for up to 6
- First choice of table placement
- Admittance to the Friday evening welcome reception
- Recognition as a Presenting sponsor on website, and welcome PowerPoint – Name only, no logos
- Sponsor level ribbon – Presenting
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
- Opportunity to conduct a non CME Satellite Symposium during lunch on Saturday
Platinum: $10,000 (six available)
- Three 6’ draped display tables
- Complimentary registration for up to 6
- First choice of table placement
- Admittance to the Friday evening welcome reception
- Participation in non CME Lightning Round Industry Education Session on Saturday
- Recognition as a Platinum sponsor on website, and welcome PowerPoint – Name only, no logos
- Sponsor level ribbon – Platinum
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
Gold: $7,500
- Two 6’ draped display table
- Complimentary registration for up to 4
- Admittance to the educational sessions
- Admittance to the Friday evening welcome reception
- Recognition as a Gold sponsor on website, and welcome PowerPoint – Name only, no logos
- Sponsor level ribbon – Gold
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
Silver: $5,000
- One 6’ draped display table
- Complimentary registration for 2
- Admission to the educational sessions
- Admittance to the Friday evening welcome reception
- Recognition as a Silver sponsor on website, and welcome PowerPoint – Name only, no logos
- Sponsor level ribbon – Silver
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
Standard Exhibitor: $2,500
- One 6’ draped display table
- Complimentary registration for 1
- Two breaks and lunch break during the meeting for attendees to network
Please take a moment to complete the Exhibitor Registration Form. For additional information, please contact Melissa O'Brien mdobrien@med.unr.edu or call 775-784-1983.
CME Accreditation and Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and Renown Health. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
Continuing Medical Education Credit
The University of Nevada, Reno School of Medicine designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nevada, Reno School of Medicine approves this program for 10.00 hours of nursing continuing education credit. Nevada State Board of Nursing provider number 120894-1.
As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.
The following presenter has disclosed the following relationship with a commercial interest:
-
Tanios Bekaii Saab - Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS; (Consulting): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA, Merck, Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, Astra Zeneca, Exelixis, Merck/Eisai, PanCan and 1Globe: (Advisory Board): Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma; (Royalties) UpToDate Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
-
Christopher Evans - (Advisory Board) Pfizer, ended. Janssen, ended; (Grant/Research Support): Janssen, ended; (Speakers Bureau/Honoraria) Janssen.
-
Joseph Gzymski - (Grant Research): Gilead Sciences
-
Joyce O’Shaughnessy - (Advisory Board) : AbbVie Inc, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Byondis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, DAVA Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru; (Consultant): AbbVie Inc, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Byondis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, DAVA Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru
-
David Penberthy - (Employment by Ineligible Entity): Speaker Bureau for AstraZeneca, ROMTech investor; (Ownership Interest - privately held):ROMTech, Inc
- Edward S. Kim - Employee of: City of Hope National Medical Center, Consultant for: Mirati Therapeutics, Genentech/Roche, Aionco
All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that neither they nor their spouse/legally recognized domestic partner has any financial relationships with commercial interests related to the content of this activity.